Laurus Labs Ltd. · NSE:LAURUSLABS

Laurus Labs — Q3 & 9M FY18 Earnings Presentation

23 slides from Laurus Labs's earnings presentation, Jan 29, 2018

  1. Slide 1: Letter to exchanges: Investors/Analysts Presentation

    laurus labs limited Corporate Office 2"" Floor, Serene Chambers, Road No. 7 Banjara Hills, Hyderabad - S0003it, Telangana, India T +91 itO 3980it333/ 23it2 0500 I 501 LAURUS Labs F +91 itO 3980 it320 Knowledge . Innovation . Excellence January 29, 2018 To To The Corporate Relations Department The Li

  2. Slide 2: Q3 & 9M FY18 Results Presentation

    LAURUS LABS LIMITED Q3 & 9M FY18 RESULTS PRESENTATION 29 January - 2018

  3. Slide 3: Disclaimer

    Disclaimer Certain statements in this document may be forward-looking statements. Such forward- looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ mat

  4. Slide 4: Business Snapshot

    Business Snapshot Overview • Development, • Developing and • Contract development • Sale and manufacture of manufacture and sale of manufacturing oral solid and manufacturing specialty ingredients for active pharmaceutical formulations services for global use in nutraceuticals, ingredients (APIs) an

  5. Slide 5: Strategy in Motion

    Strategy in Motion Oncology & ARV & HEP-C Other APIs FDFs Synthesis Ingredients • Significant increase in • Leadership in select • Leverage API • Focus on supply of • Leverage process HIV patient Oncology API. capabilities; capture key starting materials chemistry skills to population with Launching

  6. Slide 6: Transformation of Business Model

    Transformation of Business Model • Incorporated Laurus Inc. at • Investment of Delaware as a Rs. 600 mn in wholly owned • Set up the R&D the Company subsidiary of our • Successfully listed on BSE & Centre at IKP, by FIL Capital company. NSE Knowledge Management • Investment of Rs • Filed first ANDA

  7. Slide 7: Significant Investments in Generic FDF Business

    Significant Investments in Generic FDF Business  Filed first ANDA and WHO dossier in 2016.  Leverage API production and R&D capabilities to forward integrate  As on date filed 8 ANDAs and in into FDF addition completed 20  Capture significant operating validations for formulations. Filings Strat

  8. Slide 8: Strong R&D Capabilities

    Strong R&D Capabilities  “Research-first” approach – Set up Key Accreditations dedicated R&D center in Hyderabad in 2006 prior to commissioning API manufacturing facility in 2007  R&D team comprising 750 plus scientists (25.0% of total employee strength) including 45 PhDs  Kilo Lab at R&D center

  9. Slide 9: Quality Focus & Regulatory Audits

    Quality Focus & Regulatory Audits - Laurus’ Philosophy “One Quality for all markets” Regular Inspection at different manufacturing units We maintain consistent quality, efficiency and 2017 WHO, USFDA, EU (Germany) product safety. 2016 USFDA We have adopted uniform manufacturing standards across all

  10. Slide 10: Manufacturing Facilities at Parawada, Vizag

    Manufacturing Facilities at Parawada, Vizag Unit-I • Located at Jawaharlal Nehru Pharma City, Vishakapatnam, India. • API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing. • 315 reactors, with 1140 Kilo Litres capacity. • Received approvals from US F

  11. Slide 11: Facilities at Achutapuram, Vizag

    Facilities at Achutapuram, Vizag Unit-II • Located at APIIC, Achutapuram, Visakhapatnam, India. (SEZ) • FDF and API manufacturing facility • FDF - capacity of 5 billion tablets per year. • API block with 12 reactors and total capacity of 84 Kilo Litres. • Received approvals from BfArM, Germany. • US

  12. Slide 12: Efficient Use of Capital and Prudent Leverage

    Established Track Record Of Delivering Growth – Efficient Use of Capital and Prudent Leverage Pre Tax Return on Capital Return on Equity(2) (%) Total Debt/Equity Ratio Employed(1) (%) (x) 41.2% 27.2% 1.5x 26.1% 31.9% 1.2x 1.1x 1.1x 16.5% 16.5% 14.5% 13.2% 0.7x 17.0% 17.4% 0.6x 12.7% 11.8% FY13 FY14

  13. Slide 13: Business Highlights

    Business Highlights Overall Generic API  Total revenues grew by 4.5 % in 9M FY18.  Successfully completed USFDA inspection for API facility in Unit 2 with out any 483 observations. Received EIR for the same  R & D spent of INR 754 million and 5.1 % as percentage of sales during 9M FY18.  Success

  14. Slide 14: Performance Highlights - Abridged Profit & Loss statement

    Performance Highlights - Abridged Profit & Loss statement Growth % Growth % Growth % (Q3 FY18 (Q2 FY18 (9M FY18 Particulars (Rs. mn) Q3 FY18 Q3 FY17 Q2 FY18 9M FY18 9M FY17 Vs. Vs. Vs. Q3 FY 17) Q3 FY 18) 9M FY 17) Total Revenues from Operations (Net) 4,789 5,056 -5.3% 5,386 -11.1% 14,959 14,319 4.5

  15. Slide 15: Drivers of Earnings – 9M FY18

    Drivers of Earnings – 9M FY 18 3,300 22.0% 21.4% 23.0% 3,200 1,800 22.0% 11.6% 13.0% 3,100 21.0% 1,700 1,300 9.0% 3,000 12.0% 8.3% 8.2% 2,900 20.0% 10.8% 1,600 19.0% 2,800 11.0% 8.0% 2,700 18.0% 1,500 2,600 17.0% 1,200 10.0% 2,500 1,400 16.0% 2,400 7.0% 2,300 15.0% 1,300 9.0% 2,200 14.0% 1,100 2,100

  16. Slide 16: Drivers of Revenue

    Drivers of Revenue Revenue Contribution  Synthesis Business reported robust 2% 2% 3% 3% 3% revenue growth with commencement 8% 6% 7% 7% 5% of initial supplies to Aspen from Unit 5. 8% 6% 9% 7% 9% 4% 6% 7% 9% 10% 8%  Oncology and Other API showed a 5% 14% very healthy growth, with improved 5% 9% vo

  17. Slide 17: Management Team

    Management Team Tom Versosky Chandrakanth Chereddi President FDF North America ED & Head, Generics FDF and Synthesis Dr. Prafulla Kumar Nandi SVP, Global Regulatory Ravikumar V V G Venkateshwar Reddy Affairs (Formulations) ED &CFO CS and Sr. GM – Legal & Secretarial Dr. Lakshmana Rao C V Exec .VP –

  18. Slide 18: Corporate Governance

    Corporate Governance Executive Directors Name Background Dr. Satyanarayana Chava  Whole-time Director, Founder and Chief Executive Officer Dr. Raju Srihari Kalidindi  Whole-time Director and Head of Generics – API & Ingredients Ravi Kumar V V  Whole-time Director and CFO Chandrakanth Chereddi  W

  19. Slide 19: Fortune 500 company & Best Place To Work

    Laurus Labs is a Fortune 500 company & also the Best Place To Work in 2018 Laurus Labs is listed in the Fortune 500 Laurus Labs is certified as “Great Place to Companies List in India Work” for the year 2018. 18

  20. Slide 20: Ownership Structure

    Ownership Structure Corporate Structure Laurus Labs Limited Laurus Synthesis Sriam Labs Pvt Laurus Holdings All are 100% Inc. Ltd. Ltd. Subsidiaries USA India UK Laurus Generics Inc. USA Shareholding pattern * 30.6% 7.5% 10.4% 1.2% 0.03% 19.8% 11.6% 18.9% Promoter Financial Non- Foreign Institutions

  21. Slide 21: Results Conference Call

    Results Conference Call Results conference call on Tuesday January 30, 2018 at 5:00 PM IST Details of the conference call are as follows: Timing 5:00 PM IST on Tuesday, January 30, 2018 Conference dial-in Primary number +91 22 3938 1071 India Local access Number +91 704 5671221 Available all over In

  22. Slide 22: Contact us

    Contact us About Laurus Labs Ltd. Laurus Labs is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti- retroviral (ARV) and Hepatitis C. Laurus als

  23. Slide 23: Thank You

    Thank You

Laurus Labs — Q3 & 9M FY18 Earnings Presentation on 6ix